Shares of Sun Pharmaceutical Industries and Sun Pharma Advanced Research Company gained 3-7 percent in the opening trade on Friday on the back of USFDA approval for Xelpros which is used to treat open-angle Glaucoma or Ocular Hypertension.
The company announced USFDA (US Food and Drug Administration) approval for the new drug application (NDA) of Xelprostm (latanoprost ophthalmic emulsion) 0.005% for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
This approval is from Sun Pharma’s Halol (Gujarat, India) facility.
To Get Free Trial
Missed call @ 9582541010
Call Us @ 8822117117
Mail Us = starindiamarket@gmail.com
Visit = http://www.starindiaresearch.com/freetrail.php
Missed call @ 9582541010
Call Us @ 8822117117
Mail Us = starindiamarket@gmail.com
Visit = http://www.starindiaresearch.com/freetrail.php
No comments:
Post a Comment